Drug intelligence / Profile preview

Xiaozhenfang

Development stage: Unknown
Lead developer: Jiangsu Province Hospital on Integration of Chinese and Western Medicine
Administration: Oral

Overview

Xiaozhenfang is a Traditional Chinese Medicine (TCM) herbal formula developed by the Jiangsu Province Hospital on Integration of Chinese and Western Medicine. It is prepared as a granule for oral administration and is specifically indicated for the prevention and management of dermal toxicity, such as skin rash, in patients receiving epidermal growth factor receptor inhibitors (EGFRIs) for conditions like non-small cell lung cancer (NSCLC). The formula is designed to mitigate the adverse dermatological effects of targeted therapies, thereby enhancing patient adherence and quality of life without interfering with the primary anti-tumor treatment.

Other names: Xiaozhenfang granuleXiaozhenfang prescription

Beyond the preview

Go deeper on Xiaozhenfang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiaozhenfang.

Explore the full profile